Critical Analysis: Carisma Therapeutics (CARM) & Its Peers

Carisma Therapeutics (NASDAQ:CARM – Get Rating) is one of 994 publicly-traded companies in the “Pharmaceutical preparations” industry, but how does it contrast to its rivals? We will compare Carisma Therapeutics to similar businesses based on the strength of its analyst recommendations, dividends, risk, profitability, valuation, institutional ownership and earnings.

Analyst Recommendations

This is a breakdown of current ratings for Carisma Therapeutics and its rivals, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Carisma Therapeutics	0	0	1	0	3.00
Carisma Therapeutics Competitors	4351	15335	41777	733	2.63

Carisma Therapeutics presently has a consensus target price of $10.00, indicating a potential upside of 76.99%. As a group, “Pharmaceutical preparations” companies have a potential upside of 103.02%. Given Carisma Therapeutics’ rivals higher probable upside, analysts plainly believe Carisma Therapeutics has less favorable growth aspects than its rivals.

Institutional & Insider Ownership

16.5% of Carisma Therapeutics shares are held by institutional investors. Comparatively, 40.6% of shares of all “Pharmaceutical preparations” companies are held by institutional investors. 3.2% of Carisma Therapeutics shares are held by company insiders. Comparatively, 15.6% of shares of all “Pharmaceutical preparations” companies are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Earnings and Valuation

This table compares Carisma Therapeutics and its rivals revenue, earnings per share and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Carisma Therapeutics	$3.53 million	-$19.88 million	-2.83
Carisma Therapeutics Competitors	$8.54 billion	$225.66 million	-3.74

Carisma Therapeutics’ rivals have higher revenue and earnings than Carisma Therapeutics. Carisma Therapeutics is trading at a higher price-to-earnings ratio than its rivals, indicating that it is currently more expensive than other companies in its industry.

Profitability

This table compares Carisma Therapeutics and its rivals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Carisma Therapeutics	N/A	6.70%	5.41%
Carisma Therapeutics Competitors	-3,252.01%	-239.66%	-35.23%

Risk and Volatility

Carisma Therapeutics has a beta of 0.81, suggesting that its stock price is 19% less volatile than the S&P 500. Comparatively, Carisma Therapeutics’ rivals have a beta of 0.84, suggesting that their average stock price is 16% less volatile than the S&P 500.

Summary

Carisma Therapeutics rivals beat Carisma Therapeutics on 7 of the 13 factors compared.

About Carisma Therapeutics

(Get Rating)

Carisma Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the discovery and development of immunotherapies. It offers chimeric antigen receptor (CAR)-macrophages, a cell therapy platform focusing on the treatment of solid tumors. The company was founded by Michael Klichinsky and Saar Gill in 2016 and is headquartered in Philadelphia, PA.